Tuberculosis surveillance for a world health crisis
Tuberculosis (TB) surveillance is a vital step toward eradicating a disease that is the second leading infectious disease killer worldwide, behind COVID-19.1 Caused by bacteria in the Mycobacterium tuberculosis complex (MTBC), which includes Mycobacterium tuberculosis (Mtb), TB is a treatable disease but multidrug-resistant TB (MDR-TB) remains a public health crisis and a health security threat.1 Genomic-based TB surveillance can support public health officials in:
- Detecting Mtb and non-TB species
- Characterizing anti-TB drug resistance
- Tracking the path of transmission
- Monitoring the evolution of the mycobacterium and novel mutations that are resistant to existing and new forms of treatment
- The discriminatory power of next-generation sequencing (NGS) enabling outbreaks to be addressed with greater speed and confidence.
In Indonesia, a former patient turns his efforts toward helping others beat the second-leading infectious disease killer worldwide.
July 2023: World Health Organization (WHO) issues rapid communication on use of targeted next-generation sequencing to detect drug-resistant tuberculosis
Key highlights from the document:
- The available evidence supports the use of targeted NGS to detect drug resistance after TB diagnosis.
- For Genoscreen Deeplex® Myc-TB , all of the 10 drugs evaluated met the class-based performance criteria: rifampicin, isoniazid, pyrazinamide, ethambutol, fluoroquinolones, bedaquiline, linezolid, clofazimine, amikacin and streptomycin.
- Overall targeted NGS was found to be:
- Accurate
- Cost-effective (context-dependent)
- Acceptable and implementable under routine conditions, despite inherent complexity
Illumina and GenoScreen partner to expand access to genomic testing for multidrug-resistant tuberculosis
Illumina and Genoscreen Deeplex Myc-TB Combo Kit- A comprehensive, culture-free solution to characterize TB drug resistance with fast results in less than 48 hours.
Explore the benefits of Illumina and GenoScreen Deeplex Myc-TB Combo Kit in one glance.
Genomic analysis for detecting drug-resistant tuberculosis
Join the fight against drug-resistant tuberculosis (DR-TB) and unlock the full potential of next-generation sequencing (NGS) with our educational eBook and infographic. Providing an overview of the disease and equipping you with cutting-edge techniques to fuel DR-TB research, enhance TB surveillance, and ultimately paving the way to eradicate this global threat.
New Tuberculosis Surveillance eBook
Infographic for Key Advantages
TB Expert Webinars and Interviews
Advancing the fight against tuberculosis with NGS
In this webinar, Prof. Tim Rodwell, Prof. Vitali Sintchenko and Dr. Melanie Grobbelaar will discuss how NGS including WGS and tNGS can advance the fight against TB.
Fighting drug-resistant tuberculosis in South Africa
Dr. Shaheed Vally Omar: Next-generation sequencing is the best weapon for comprehensively tracking MDR-TB.
Inside a Mumbai lab using genomics for TB surveillance
How whole-genome sequencing can quickly detect TB drug resistance—and help India wipe out TB in the next two years.
Seeking the source of bacterial drug resistance
Dr. Phillip Supply explores the growing problem of MDR-TB and the value of the Deeplex Myc-TB targeted NGS assay in TB surveillance and rapid detection of TB drug resistance.
References
- World Health Organization. (2022). Global Tuberculosis Report 2022. Retrieved March 9, 2023, from https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2022
- Castro RAD, Borrell S, Gagneux S. The within-host evolution of antimicrobial resistance in Mycobacterium tuberculosis. FEMS Microbiol Rev. 2021 Aug 17;45(4) doi: 10.1093/femsre/fuaa071
M-APJ-00206